Back

Heart failure prevalence, medication prescription rates, and adverse outcomes in patients undergoing TAVI: the real-world data analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Epidemiology of heart failure Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Elena Surkova

AstraZeneca, Cambridge (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Temporal trends and breakpoints in age standardized DAYS rates for ischemic heart disease global and country level analysis from 1990 to 2021
Doctor M. Khan (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
Comorbidity burden predicts admission on an intensive care unit in heart failure patients
Mrs A. Leuschner (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Impact of covid-19 on acute heart failure admissions and in-hospital outcomes: a nationwide analysis of 2016-2021 data
Doctor M. Gatuz (Candon City, PH)
Abstract Slides Video
Presentation thumbnail
Heart failure in Poland: a 20-year epidemiological perspective
Assistant Professor M. Bohdan (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Occurrence and characteristics of pulmonary hypertension in heart failure with reduced ejection fraction undergoing right heart catheterization - high-volume centre experience
Mr F. Sawczak (Poznan, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Epidemiology of heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Improving prognosis in aortic valve disease
thumbnail
Congress Session
Improving prognosis after TAVI
thumbnail
Congress Session
Predictors of outcomes in transcatheter aortic valve implantation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources